Recent Finacing
Recent Raise
Code Biotherapeutics develops a synthetic multivalent non-viral DNA delivery platform (3DNA) for tissue-targeted, re-dosable gene delivery and advances internal DMD and T1D therapy programs, scaling manufacturing.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Code Biotherapeutics.
